EVFM Evofem Biosciences Inc.

4.99
+0.16  (+3%)
Previous Close 4.83
Open 4.95
Price To Book 249.5
Market Cap 248,007,646
Shares 49,700,931
Volume 8,139,234
Short Ratio
Av. Daily Volume 451,104
Stock charts supplied by TradingView

NewsSee all news

  1. U.S. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy

    SAN DIEGO, May 22, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM) today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate)

  2. PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders

    INCLINE VILLAGE, Nev., May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) announces that it has completed its previously announced distribution of all of the

  3. PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders

    INCLINE VILLAGE, Nev., May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) announces the final distribution ratio for the previously announced distribution of all of

  4. Evofem Biosciences to Participate in Virtual Fireside Chat at RBC Capital Markets Global Healthcare Conference

    SAN DIEGO, May 13, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that it will participate in the upcoming 2020 RBC Capital Markets Global

  5. Evofem Biosciences Reports First Quarter 2020 Financial Results and Provides Corporate Update

    SAN DIEGO, May 6, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today reported financial results for the three-month period ended March 31, 2020.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data met primary endpoint - December 2, 2019.
Amphora - AMPREVENCE
Prevention of urogenital Chlamydia trachomatis infection in women
FDA Approval announced May 22, 2020.
Amphora - AMPOWER
contraceptive vaginal gel

Latest News

  1. U.S. FDA Approves Evofem Biosciences' Phexxi™ (lactic acid, citric acid and potassium bitartrate), the First and Only Non-Hormonal Prescription Gel for the Prevention of Pregnancy

    SAN DIEGO, May 22, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM) today announced that the U.S. Food and Drug Administration (FDA) has approved Phexxi™ (lactic acid, citric acid and potassium bitartrate)

  2. PDL BioPharma Completes Distribution of Evofem Biosciences Common Stock to PDL Stockholders

    INCLINE VILLAGE, Nev., May 21, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) announces that it has completed its previously announced distribution of all of the

  3. PDL BioPharma Declares Distribution Ratio for Dividend of Evofem Biosciences Common Stock to PDL Stockholders

    INCLINE VILLAGE, Nev., May 18, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) announces the final distribution ratio for the previously announced distribution of all of

  4. Evofem Biosciences to Participate in Virtual Fireside Chat at RBC Capital Markets Global Healthcare Conference

    SAN DIEGO, May 13, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that it will participate in the upcoming 2020 RBC Capital Markets Global

  5. Evofem Biosciences Reports First Quarter 2020 Financial Results and Provides Corporate Update

    SAN DIEGO, May 6, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today reported financial results for the three-month period ended March 31, 2020.

  6. PDL BioPharma Declares Dividend of Evofem Biosciences Common Stock to PDL Stockholders

    INCLINE VILLAGE, Nev., May 5, 2020 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or "the Company") (NASDAQ:PDLI) announces that the Company's Board of Directors has approved a distribution of all of the

  7. Evofem Biosciences Announces New Location and COVID-19 Preventative Measures for 2020 Annual Meeting Scheduled for May 12, 2020

    SAN DIEGO, May 1, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that the location of its annual general meeting scheduled for May 12, 2020 at

  8. Evofem Biosciences to Report First Quarter 2020 Results and Provide Corporate Update on Wednesday, May 6, 2020

    SAN DIEGO, April 28, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that it will host a webcast and conference call to discuss the Company's

  9. Evofem Biosciences Secures up to $25 Million in Convertible Note Financing

    SAN DIEGO, April 27, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that it has entered into a private Securities Purchase Agreement with a

  10. Evofem Biosciences Announces Three New Phexxi™ Data Sets Accepted for Presentation at the 2020 American College of Obstetricians and Gynecologists (ACOG) Annual Meeting

    SAN DIEGO, April 24, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that three new data sets from the Company's Phase 3 AMPOWER trial

  11. Evofem Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    SAN DIEGO, April 10, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that on April 9, 2020, the Compensation Committee of the Company's Board

  12. Solebury Trout Announces Additional Virtual Conference Presentations from Life Science Companies on April 7, 2020

  13. Evofem Biosciences to Present at Solebury Trout Virtual Investor Conference

    SAN DIEGO, March 27, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present an overview of the

  14. Evofem Biosciences Adopts Shareholder Rights Agreement

    SAN DIEGO, March 25, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that its Board of Directors has adopted a shareholder rights agreement

  15. Solebury Trout Announces Virtual Conference Series with Presentations from Life Science Companies

    NEW YORK, NY / ACCESSWIRE / March 24, 2020 / Solebury Trout, a boutique investor relations and corporate communications firm, announced today that it will be hosting a Virtual Conference Series on March 26, March 31, and

  16. TRACON Pharmaceuticals Announces Appointment of Saundra Pelletier to Board of Directors

    SAN DIEGO, March 19, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer

  17. Evofem Biosciences Reports Fourth Quarter and Year-end 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, March 12, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today reported financial results for the three- and twelve- month periods ended December 31,

  18. Evofem Biosciences to Report Fourth Quarter and Year-end 2019 Results and Provide Corporate Update on March 12, 2020

    SAN DIEGO, March 3, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM) will hold a webcast and conference call to discuss the Company's financial results and business highlights for the fourth quarter and

  19. Evofem Biosciences Appoints Former FDA Division Director Lisa Rarick, M.D., to its Board of Directors

    SAN DIEGO, Feb. 26, 2020 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced the appointment of Lisa Rarick, M.D., F.A.C.O.G., to its Board of Directors.

  20. U.S. FDA Acknowledges Receipt of Evofem Biosciences' New Drug Application Resubmission for Amphora® for the Prevention of Pregnancy

    SAN DIEGO, Dec. 18, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) acknowledged receipt of the

  21. PDL BioPharma Congratulates Evofem Biosciences on Achieving Major Regulatory and Clinical Milestones with its Lead Product Candidate Amphora®

    INCLINE VILLAGE, Nev., Dec. 3, 2019 /PRNewswire/ -- PDL BioPharma, Inc. ("PDL" or the "Company") (NASDAQ:PDLI) congratulates Evofem Biosciences, Inc. ("Evofem") (NASDAQ:EVFM) on its recent

  22. Evofem Biosciences Reports Positive Top-Line Results from Phase 2b Study of Amphora® for Prevention of Chlamydia and Gonorrhea in Women

    SAN DIEGO, Dec. 2, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical stage biopharmaceutical company, today announced positive top-line results from AMPREVENCE, a Phase 2b clinical trial evaluating

  23. Evofem Biosciences Resubmits New Drug Application to U.S. FDA for Amphora® for the Prevention of Pregnancy

    SAN DIEGO, Nov. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, today announced that it has resubmitted its New Drug Application (NDA) to the U.S. Food and

  24. Evofem Biosciences' CEO Saundra Pelletier Awarded 2019 Business Woman Of The Year

    SAN DIEGO, Nov. 14, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) today announced that Chief Executive Officer Saundra Pelletier was named a 2019 Business Woman of the Year by the San Diego Business

  25. Evofem Biosciences to Participate in Upcoming Investor Conferences

    SAN DIEGO, Nov. 13, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, announced today that Chief Executive Officer Saundra Pelletier will present at two upcoming

  26. Evofem Biosciences Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    SAN DIEGO, Nov. 6, 2019 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ:EVFM) a clinical-stage biopharmaceutical company, today reported financial results for the three- and nine-month periods ended September 30, 2019.

  27. Evofem Biosciences to Present at Cantor Global Healthcare Conference on October 4, 2019

    SAN DIEGO, Sept. 25, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, will present and host investor meetings at the upcoming 2019 Cantor Global Healthcare

  28. Microbiotica Appoints Thomas Lynch as Independent Non-Executive Chairman

    Microbiotica, a leading player in microbiome-based therapeutics and biomarkers, announces the appointment of Thomas Lynch as the new non-Executive Chairman of its Board, from 1 September 2019.

  29. Evofem Biosciences Completes Phase 2b 'AMPREVENCE' Trial of Amphora for Prevention of Chlamydia and Gonorrhea in Women

    SAN DIEGO, Aug. 26, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM) ("Evofem" or the "Company") today announced the last patient has completed her last visit in AMPREVENCE, the Phase 2b

  30. Evofem Biosciences to Present at Upcoming Healthcare Conferences

    SAN DIEGO, Aug. 22, 2019 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ:EVFM), a clinical-stage biopharmaceutical company, is set to present at two healthcare equity conferences in early September.